Journal
EUROPEAN UROLOGY
Volume 69, Issue 4, Pages 551-554Publisher
ELSEVIER
DOI: 10.1016/j.eururo.2015.09.039
Keywords
Benign prostatic hyperplasia; Telomerase; Stem cells
Categories
Funding
- Prostate Cancer UK [G2012-37]
- PRO-NEST Marie-Curie network
- Yorkshire Cancer Research [Y257PA]
- Orchid Trust
- Prostate Cancer UK [G2012-37] Funding Source: researchfish
Ask authors/readers for more resources
Benign prostatic hyperplasia (BPH) treatments have changed little over many years and do not directly address the underlying cause. Because BPH is characterised by uncontrolled cell growth, the chromosomal telomeres should be eroded in the reported absence or low levels of telomerase activity, but this is not observed. We investigated the telomere biology of cell subpopulations from BPH patients undergoing transurethral resection of prostate (TURP). Measurement of TERC, TERT, and telomerase activity revealed that only the epithelial stem-like and progenitor fractions expressed high levels of telomerase activity (p < 0.01) and individual enzyme components (p < 0.01). Telomerase activity and TERT expression were not detected in stromal cells. Telomere length measurements reflected this activity, although the average telomere length of (telomerase-negative) luminal cells was equivalent to that of telomerase-expressing stem/progenitor cells. Immunohistochemical analysis of patient-derived BPH arrays identified distinct areas of luminal hyperproliferation, basal hyperproliferation, and basal-luminal hyperproliferation, suggesting that basal and luminal cells can proliferate independently of each other. We propose a separate lineage for the luminal and basal cell components in BPH. (C) 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available